Amin NB, Frederich R, Tsamandouras N, Haggag AZ, et al. Evaluation of an oral small-molecule glucagon-like peptide-1 receptor agonist, lotiglipron, for type 2 diabetes and obesity: A dose-ranging, phase 2, randomized, placebo-controlled study. Diabetes Obes Metab 2024 Oct 16. doi: 10.1111/dom.16005.
PMID: 39415344